摘要
背景:目前没有药物可以减缓阿尔茨海默病患者的神经变性过程或减轻认知和抑郁症状。由于阿尔茨海默病患者数量的增加,迫切需要开发具有神经保护、促认知和抗抑郁特性的新型药物。 目的:本研究的目的是设计、合成和评估具有 5-羟色胺 5-HT1A/5-HT7 受体亲和力和磷酸二酯酶 (PDE) 抑制活性的新型氨基烷酰胺,作为对抗神经变性和阿尔茨海默病症状的新方法。
方法:使用经典的有机化学方法合成新设计的化合物,并在体外测试其受体亲和力、功能特征、酶抑制和 ADME 特性。在 SH-SY5Y 细胞中测试了对 H2O2 诱导的活性氧水平增加的神经保护作用。新的物体识别和强迫游泳测试分别用于评估预测和抗抑郁活性。
结果:合成的氨基烷酰胺被表征为有效的 5-HT1A 受体拮抗剂,具有额外的 5-HT7 受体拮抗特性和 PDE4B 抑制活性。选定的化合物 15 显示出神经保护、促认知和抗抑郁特性。此外,化合物 15 显示出合适的 ADME 特性,表现为良好的膜渗透性和高代谢稳定性。
结论:这项研究揭示了一类新的化合物,它们可能有助于寻找一种有效的药物来缓解神经变性和阿尔茨海默病的症状。
关键词: 阿尔茨海默病、ADME 特性、氨基烷酰胺、体内研究、神经保护、磷酸二酯酶抑制剂、血清素受体配体。
Current Medicinal Chemistry
Title:Design and Synthesis of Novel Aminoalkanamides Targeting Neurodegeneration and Symptoms of Alzheimer’s Disease
Volume: 28 Issue: 29
关键词: 阿尔茨海默病、ADME 特性、氨基烷酰胺、体内研究、神经保护、磷酸二酯酶抑制剂、血清素受体配体。
摘要:
Background: There is currently no drug that slows the process of neurodegeneration or alleviates the cognitive and depressive symptoms in patients with Alzheimer’s disease. Due to the increasing number of Alzheimer’s patients, there is an urgent need to develop novel drugs with neuroprotective, procognitive, and antidepressant properties.
Objective: The aim of this study was to design, synthesize, and evaluate novel aminoalkanamides with serotonin 5-HT1A/5-HT7 receptor affinity and phosphodiesterase (PDE) inhibitory activity as a new approach to combat neurodegeneration and symptoms of Alzheimer’s disease.
Methods: The newly designed compounds were synthesized using classical methods of organic chemistry and tested in vitro for their receptor affinity, functional profile, enzyme inhibition, and ADME properties. The neuroprotective effect against H2O2-induced increase of reactive oxygen species level was tested in SH-SY5Y cells. The novel object recognition and forced swimming tests were used to evaluate the procognitive and antidepressant activity, respectively.
Results: Synthesized aminoalkanamides were characterized as potent 5-HT1A receptor antagonists with additional 5-HT7 receptor antagonistic properties and PDE4B inhibitory activity. Selected compound 15 showed neuroprotective, procognitive, and antidepressant properties. In addition, compound 15 revealed suitable ADME properties expressed as good membrane permeability and high metabolic stability.
Conclusion: This study revealed a new class of compounds that may be useful in the search for an effective drug in the alleviation of neurodegeneration and symptoms of Alzheimer’s disease.
Export Options
About this article
Cite this article as:
Design and Synthesis of Novel Aminoalkanamides Targeting Neurodegeneration and Symptoms of Alzheimer’s Disease, Current Medicinal Chemistry 2021; 28 (29) . https://dx.doi.org/10.2174/0929867328666210215113346
DOI https://dx.doi.org/10.2174/0929867328666210215113346 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Adrenomedullin and Nitric Oxide: Implications for the Etiology and Treatment of Primary Brain Tumors
CNS & Neurological Disorders - Drug Targets Comparison of Various Types of Ligand Decorated Nanoliposomes for their Ability to Inhibit Amyloid Aggregation and to Reverse Amyloid Cytotoxicity
Current Topics in Medicinal Chemistry Modulation of Sirtuins: New Targets for Antiageing
Recent Patents on CNS Drug Discovery (Discontinued) Perinatal Management of Fetal Tumors
Current Pediatric Reviews Current Status and Future Perspective for Research on Medicinal Plants with Anticancerous Activity and Minimum Cytotoxic Value
Current Drug Targets Neuropharmacological Aspects of Crocus sativus L.: A Review of Preclinical Studies and Ongoing Clinical Research
CNS & Neurological Disorders - Drug Targets Estrogen Receptor Signaling: Impact on Cell Functions
Current Signal Transduction Therapy Beyond Cholinesterase Inhibition: Anti-Inflammatory Role and Pharmacological Profile of Current Drug Therapy for Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Cordycepin in Anticancer Research: Molecular Mechanism of Therapeutic Effects
Current Medicinal Chemistry Rapid Non-genomic Vasodilator Actions of Oestrogens and Sex Steroids
Current Medicinal Chemistry Novel Pharmacodynamic Approach to Assess Obatoclax (GX15-070) and Bortezomib (BTZ) Synergism in Non-Hodgkin’s Lymphoma
Clinical Cancer Drugs Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update
Current Medicinal Chemistry Levetiracetam might act as an efficacious drug to attenuate cognitive deficits of Alzheimer’s disease
Current Topics in Medicinal Chemistry New Approaches to the Modulation of the Cyclooxygenase-2 and 5-Lipoxygenase Pathways
Current Topics in Medicinal Chemistry Histone Modifications, Stem Cells and Prostate Cancer
Current Pharmaceutical Design The PI3K/Akt/mTOR Pathway as Therapeutic Target in Neuroblastoma
Current Cancer Drug Targets Histone Deacetylase Inhibitors in Cancer Treatment: A Review of the Clinical Toxicity and the Modulation of Gene Expression in Cancer Cells
Current Pharmaceutical Biotechnology MicroRNAs: Key Players in Microglia and Astrocyte Mediated Inflammation in CNS Pathologies
Current Medicinal Chemistry The Crosstalk of RAS with the TGF-β Family During Carcinoma Progression and its Implications for Targeted Cancer Therapy
Current Cancer Drug Targets Implication of Green Tea as a Possible Therapeutic Approach for Parkinson Disease
CNS & Neurological Disorders - Drug Targets